Christian Todd Nichols Sells 5,208 Shares of Alkermes plc (NASDAQ:ALKS) Stock

Alkermes plc (NASDAQ:ALKS) SVP Christian Todd Nichols sold 5,208 shares of Alkermes stock in a transaction on Wednesday, November 27th. The stock was sold at an average price of $29.15, for a total transaction of $151,813.20. Following the transaction, the senior vice president now owns 60,703 shares in the company, valued at approximately $1,769,492.45. This trade represents a 7.90 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink.

Alkermes Price Performance

ALKS stock opened at $29.32 on Friday. Alkermes plc has a 1 year low of $22.22 and a 1 year high of $32.88. The stock has a market capitalization of $4.74 billion, a PE ratio of 15.04, a price-to-earnings-growth ratio of 0.98 and a beta of 0.47. The company’s 50-day moving average is $28.00 and its 200-day moving average is $26.49. The company has a debt-to-equity ratio of 0.22, a current ratio of 3.45 and a quick ratio of 3.03.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently added to or reduced their stakes in the company. O Shaughnessy Asset Management LLC raised its position in shares of Alkermes by 21.2% during the first quarter. O Shaughnessy Asset Management LLC now owns 11,976 shares of the company’s stock worth $324,000 after purchasing an additional 2,097 shares during the period. Advisors Asset Management Inc. lifted its stake in shares of Alkermes by 19.6% in the first quarter. Advisors Asset Management Inc. now owns 29,886 shares of the company’s stock valued at $809,000 after buying an additional 4,891 shares in the last quarter. Lazard Asset Management LLC lifted its stake in shares of Alkermes by 655.0% in the first quarter. Lazard Asset Management LLC now owns 77,102 shares of the company’s stock valued at $2,087,000 after buying an additional 66,890 shares in the last quarter. Bayesian Capital Management LP acquired a new position in shares of Alkermes during the first quarter valued at about $333,000. Finally, Tidal Investments LLC bought a new stake in shares of Alkermes during the first quarter worth about $441,000. Institutional investors own 95.21% of the company’s stock.

Analyst Ratings Changes

A number of equities analysts have recently issued reports on ALKS shares. Mizuho raised their price objective on Alkermes from $35.00 to $40.00 and gave the stock an “outperform” rating in a research report on Wednesday, November 13th. HC Wainwright restated a “neutral” rating and set a $37.00 price target on shares of Alkermes in a report on Friday, October 25th. Piper Sandler restated an “overweight” rating and issued a $37.00 price target (down previously from $38.00) on shares of Alkermes in a research report on Friday, October 25th. The Goldman Sachs Group decreased their price objective on shares of Alkermes from $32.00 to $30.00 and set a “buy” rating for the company in a research report on Friday, October 25th. Finally, JPMorgan Chase & Co. dropped their target price on shares of Alkermes from $32.00 to $26.00 and set a “neutral” rating on the stock in a report on Friday, October 25th. One investment analyst has rated the stock with a sell rating, three have given a hold rating and nine have given a buy rating to the company’s stock. According to data from MarketBeat.com, Alkermes currently has a consensus rating of “Moderate Buy” and a consensus target price of $35.42.

About Alkermes

Alkermes plc, a biopharmaceutical company, researches, develops, and commercializes pharmaceutical products to address unmet medical needs of patients in therapeutic areas in the United States, Ireland, and internationally. It has a portfolio of proprietary commercial products for the treatment of alcohol dependence, opioid dependence, schizophrenia and bipolar I disorder and a pipeline of clinical and preclinical product candidates in development for neurological disorders.